- Organizations: Viatris
Pipeline
FDA accepts sNDA of phentolamine 0.75% for presbyopia
Already FDA-approved and commercially available as RYZUMVI, the eye drop has been assigned a PDUFA date of Oct. 17, 2026.
Products
Viatris launches RYZUMVI in the United States
As the first and only commercially available treatment for reversal of mydriasis (RM), the eye drop is now available through four distributors.
Pipeline
FDA grants SPA agreement to Ocuphire for phase 3 trial on phentolamine solution
LYNX-2 study is anticipated to begin enrollment in Q1 2024 for the treatment of dim light or night vision disturbances.
Legal
Regeneron wins Eylea patent case
Company sued Viatris over patent infringement of a proposed biosimilar in 2022.
Products
Viatris launches national consumer campaign for Tyrvaya
Resources target patient education surrounding the first and only prescription-based nasal spray to treat the signs and symptoms of DED.
Products
FDA approves Ocuphire and Viatris's RYZUMVI for RM
RYZUMVI is now the only commercially available treatment option in the U.S. indicated for the reversal of mydriasis (RM).
Business
Viatris appoints new CEO
Scott A. Smith will assume leadership this spring.
Business
Viatris officially acquires Oyster Point Pharma, Famy Life Sciences
The company now owns the rights to Tyrvaya as part of its newly established Viatris Eye Care Division.Business